Saturday 17 October 2026
Export XAGE’s income statement to Excel — free account
Longevity Health Holdings, Inc.
XAGE Consumer Defensive Household & Personal Products
Longevity Health Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, up 3,702.8% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS grew 51.3% and free cash flow grew 73.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.11
0.00
0.00%
Follow XAGE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.84 | 0.22 | 0.31 | 0.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.85) | (1.40) | (1.14) | (2.87) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.11 | 0.64 | 0.97 | 1.25 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.42) | (0.37) | (0.57) | (0.86) | |
EV/FCF |
(0.42) | (0.36) | (0.56) | (0.85) | |
Quick Ratio |
0.21 | 0.09 | 0.04 | 0.01 | |
Current Ratio |
0.42 | 0.25 | 0.15 | 0.07 | |
Net Debt/EBITDA |
0.77 | 0.32 | 0.24 | 0.05 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.51 | 1.00 | 0.72 | 0.71 | |
Operating CF/Net income |
1.00 | 0.15 | 0.34 | 0.12 | |
Capex/Depreciation |
(0.38) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(288.43) | (405.57) | (379.57) | (329.18) | |
Research and Development Expense of Revenue |
53.53% | 28.63% | 14.17% | 18.54% | |
Selling, General and Administrative Expense of Revenue |
347.78% | 504.74% | 381.57% | 220.45% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
44.59% | 40.95% | 37.24% | 19.90% | |
Graham Net Nets |
(3.62) | (14.65) | (13.20) | (14.05) | |
Graham Number |
16.55 | 21.62 | 18.72 | 16.61 | |
Earnings Yield |
(743.13%) | (1,686.67%) | (1,479.31%) | (1,342.31%) | |
Free Cash Flow Yield |
(313.80%) | (779.59%) | (558.25%) | (382.80%) | |
Revenue per Share |
0.25 | 0.33 | 0.21 | 0.16 | |
Operating CF per Share |
(0.83) | (0.21) | (0.26) | (0.09) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.84) | (0.21) | (0.26) | (0.09) | |
Cash per Share |
0.64 | 0.49 | 0.17 | 0.01 | |
Shareholders Equity per Share |
(2.31) | (4.10) | (3.63) | (3.51) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.31) | (4.10) | (3.63) | (3.51) | |
Free Cash Flow |
(1.45) | (0.31) | (0.49) | (0.22) | |
Working Capital |
(4.00) | (5.97) | (7.09) | (8.88) | |
Capital Expenditures |
(0.01) | 0.00 | — | — | |
Net Current Asset Value |
(4.43) | (6.28) | (7.27) | (9.04) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.28 | 0.17 | 0.22 | 0.19 | |
Average Payables |
4.19 | 4.28 | 4.82 | 4.82 | |
Average Inventory |
0.56 | 0.54 | 1.06 | 0.89 | |
Average Assets |
2.87 | 1.92 | 2.49 | 2.39 | |
Average Common Equity |
(4.02) | (5.29) | (5.35) | (6.22) |
Columns are period end dates